JCR Pharmaceuticals Co., Ltd.
Clinical trials sponsored by JCR Pharmaceuticals Co., Ltd., explained in plain language.
A Japanese pharmaceutical company specializing in rare disease therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a new enzyme therapy tame MPS II over time? Results expected Dec 2026 (estimated)
-
Can a new enzyme therapy tame MPS II over time?
Disease control OngoingThis study tests the long-term safety and effects of JR-141, an enzyme replacement therapy, in people with mucopolysaccharidosis II (MPS II), a rare genetic disorder. Participants who completed an earlier JR-141 trial receive the drug again by IV infusion. Researchers track side …
Phase 2 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a weekly infusion reach the brain to fight a rare childhood disease?
Disease control OngoingThis trial tests an experimental drug called JR-441 in children with mucopolysaccharidosis type IIIA (MPS IIIA), a rare genetic condition that harms the brain and body. Researchers give the drug as a weekly intravenous infusion to see if it is safe and tolerable. They also measur…
Phase 1/2 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a weekly infusion slow the toll of a rare genetic disease?
Disease control OngoingThis trial tests whether JR-141, an enzyme replacement therapy given as a weekly IV infusion, can safely manage mucopolysaccharidosis type II (MPS II) over the long term. Researchers will follow about 27 people who completed an earlier JR-141 study, tracking side effects, develop…
Phase 2/3 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for hunter syndrome: Brain-Targeting drug in final testing
Disease control OngoingThis Phase 3 study tests a new drug called JR-141 against the current standard treatment (idursulfase) in 86 people with Hunter syndrome (MPS II). The goal is to see if JR-141 can better reduce harmful substances in the brain and improve thinking skills. Participants can switch t…
Phase 3 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Hunter syndrome drug JR-141 tested for Long-Term safety
Disease control By invitation onlyThis study is an extension of a previous trial testing JR-141, a drug given weekly by IV, for people with Hunter syndrome (a rare genetic disorder). It aims to see if the drug remains safe and effective over a longer period. About 80 participants who completed the earlier study w…
Phase 3 • Sponsor: JCR Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC